Skip to main
ACET
ACET logo

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 71%
Buy 21%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio Inc's promising pipeline, particularly the preclinical candidate ADI-270, shows potential advantages in safety and efficacy over traditional αβ CAR-T therapies, suggesting a robust risk-benefit profile for patients with renal cell carcinoma and potentially other indications. The FDA's Fast Track Designation for ADI-001 underscores the therapeutic promise of the company’s allogeneic gamma delta T cell therapies, particularly for autoimmune diseases like systemic sclerosis. Additionally, Adicet's strong cash position of $176.3 million provides the necessary financial stability to continue advancing its clinical programs and enhance shareholder value.

Bears say

Adicet Bio Inc faces significant challenges due to a lack of differentiating clinical data for its drug candidates and the potential approval of competitive therapies, which could hinder future sales potential. Additionally, the company reported a fourth quarter earnings per share (EPS) loss of ($0.32), indicating financial strain, despite ending the quarter with $176.3 million in cash and cash equivalents. The overall high failure rate of drugs in clinical development adds further regulatory and competitive risks to the company's prospects.

ACET has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 21% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 14 analysts, ACET has a Strong Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.